RSS feed

Publications (original articles or review articles) published in 2023 from OUS - Department of Gynaecological Oncology

23 publications found

Berek JS, Matias-Guiu X, Creutzberg C, Fotopoulou C, Gaffney D, Kehoe S, Lindemann K, Mutch D, Concin N, Endometrial Cancer Staging Subcommittee, FIGO Women's Cancer Committee (2023)
FIGO staging of endometrial cancer: 2023
Int J Gynaecol Obstet, 162 (2), 383-394
DOI 10.1002/ijgo.14923, PubMed 37337978

Berek JS, Matias-Guiu X, Creutzberg C, Fotopoulou C, Gaffney D, Kehoe S, Lindemann K, Mutch D, Concin N, Endometrial Cancer Staging Subcommittee, FIGO Women's Cancer Committee (2023)
FIGO staging of endometrial cancer: 2023
J Gynecol Oncol, 34 (5), e85
DOI 10.3802/jgo.2023.34.e85, PubMed 37593813

Bilir E, Ahmed W, Kacperczyk-Bartnik J, Nasser S, Bjerre Trent P, Boria F, Tsibulak I, Chacon E, Martinelli F, Strojna AN, Morgan G, Bizzarri N, Eriksson AG, Theofanakis C (2023)
Social media ambassadors and collaboration with OncoAlert: a European Network of Young Gynae Oncologists study of comparative Twitter analysis of #ESGO2021 and #ESGO2022
Int J Gynecol Cancer, 33 (6), 964-970
DOI 10.1136/ijgc-2023-004371, PubMed 37130625

Bjerre Trent P, Falk RS, Staff AC, Jorde D, Eriksson AG (2023)
Translation and cross-cultural adaptation of the Gynecologic Cancer Lymphedema Questionnaire and the Lower Extremity Lymphedema Screening Questionnaire
Int J Gynecol Cancer, 33 (2), 231-235
DOI 10.1136/ijgc-2022-003979, PubMed 36600491

Bjerre Trent PK, Nordskar NJ, Wangen KR, Engeskaug MI, Opheim MLØ, Aune G, Staff AC, Thorsen L, Falk RS, Eriksson AGZ (2023)
Self-reported lower extremity lymphedema and quality of life after surgical staging of endometrial carcinoma: A population based cross-sectional study
Gynecol Oncol, 175, 72-80
DOI 10.1016/j.ygyno.2023.05.070, PubMed 37327542

Corbaux P, You B, Glasspool RM, Yanaihara N, Tinker AV, Lindemann K, Ray-Coquard IL, Mirza MR, Subtil F, Colomban O, Péron J, Karamouza E, McNeish I, Kelly C, Kagimura T, Welch S, Lewsley LA, Paoletti X, Cook A (2023)
Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis
Eur J Cancer, 191, 112966
DOI 10.1016/j.ejca.2023.112966, PubMed 37542936

Davidson B, Skeie-Jensen T, Holth A, Lindemann K, Toralba Barrameda AM, Lie AK, Wang Y (2023)
Lymphovascular invasion and p16 expression are independent prognostic factors in stage I vulvar squamous cell carcinoma
Virchows Arch (in press)
DOI 10.1007/s00428-023-03670-y, PubMed 37843640

Davidson B, Solheim O (2023)
Cancer Stem Cell Markers Are Differentially Expressed in Malignant Ovarian Germ Cell Tumors
Int J Gynecol Pathol, 42 (6), 613-619
DOI 10.1097/PGP.0000000000000947, PubMed 37186896

Dos Santos MV, Holth A, Bischof K, Davidson B (2023)
Occludin is overexpressed in tubo-ovarian high-grade serous carcinoma compared to mesothelioma and is a marker of tumor progression and chemoresistance
Clin Exp Metastasis, 41 (1), 69-76
DOI 10.1007/s10585-023-10251-5, PubMed 38141113

Dos Santos MV, Holth A, Lindemann K, Staff AC, Davidson B (2023)
Clinical significance of L1CAM expression in metastatic tubo-ovarian high-grade serous carcinoma
Gynecol Oncol, 176, 76-81
DOI 10.1016/j.ygyno.2023.07.004, PubMed 37478615

Fortner RT, Trewin-Nybråten CB, Paulsen T, Langseth H (2023)
Characterization of ovarian cancer survival by histotype and stage: A nationwide study in Norway
Int J Cancer, 153 (5), 969-978
DOI 10.1002/ijc.34576, PubMed 37226635

Fotopoulou C, Eriksson AG, Yagel I, Chang SJ, Lim MC (2023)
Surgery for Recurrent Epithelial Ovarian Cancer
Curr Oncol Rep, 26 (1), 46-54
DOI 10.1007/s11912-023-01480-8, PubMed 38091202

Grisham RN, Vergote I, Banerjee S, Drill E, Kalbacher E, Mirza MR, Romero I, Vuylsteke P, Coleman RL, Hilpert F, Oza AM, Westermann A, Oehler MK, Pignata S, Aghajanian C, Colombo N, Cibula D, Moore KN, Del Campo JM, Berger R, Marth C, Sehouli J, O'Malley DM, Churruca C, Kristensen G et al. (2023)
Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer
Clin Cancer Res, 29 (20), 4068-4075
DOI 10.1158/1078-0432.CCR-23-0621, PubMed 37581616

Joneborg U, Bergamini A, Wallin E, Mangili G, Solheim O, Marquina G, Casado A, Rokkones E, Coulter J, Lok CAR, van Trommel N, Amant F, Bolze PA, Sehouli J, Han S, Kridelka F, Goffin F, Pautier P, Ray-Coquard I, Seckl M (2023)
European multidisciplinary tumor boards support cross-border networking and increase treatment options for patients with rare gynecological tumors
Int J Gynecol Cancer, 33 (10), 1621-1626
DOI 10.1136/ijgc-2023-004599, PubMed 37783481

Karamouza E, Glasspool RM, Kelly C, Lewsley LA, Carty K, Kristensen GB, Ethier JL, Kagimura T, Yanaihara N, Cecere SC, You B, Boere IA, Pujade-Lauraine E, Ray-Coquard I, Proust-Lima C, Paoletti X (2023)
CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data
Cancers (Basel), 15 (6)
DOI 10.3390/cancers15061823, PubMed 36980708

Lindemann K, Heimisdottir Danbolt S, Ramberg L, Eyjólfsdóttir B, Wang YY, Heli-Haugestøl AG, Walcott SL, Mjåland O, Navestad GA, Hermanrud S, Juul-Hansen KE, Bragstad LK, Opheim R, Kleppe A, Kongsgaard U (2023)
Patient-reported nausea after implementation of an enhanced recovery after surgery protocol for gynae-oncology patients
Int J Gynecol Cancer, 33 (8), 1287-1294
DOI 10.1136/ijgc-2023-004356, PubMed 37451689

Lindemann K, Kleppe A, Eyjólfsdóttir B, Heimisdottir Danbolt S, Wang YY, Heli-Haugestøl AG, Walcott SL, Mjåland O, Navestad GA, Hermanrud S, Juul-Hansen KE, Kongsgaard U (2023)
Prospective evaluation of an enhanced recovery after surgery (ERAS) pathway in a Norwegian cohort of patients with suspected or advanced ovarian cancer
Int J Gynecol Cancer, 33 (8), 1279-1286
DOI 10.1136/ijgc-2023-004355, PubMed 37451690

Lundberg FE, Stensheim H, Ullenhag GJ, Sahlgren HM, Lindemann K, Fredriksson I, Johansson ALV (2023)
Risk factors for the increasing incidence of pregnancy-associated cancer in Sweden - a population-based study
Acta Obstet Gynecol Scand, 103 (4), 669-683
DOI 10.1111/aogs.14677, PubMed 37694965

Oaknin A, Gladieff L, Martínez-García J, Villacampa G, Takekuma M, De Giorgi U, Lindemann K, Woelber L, Colombo N, Duska L, Leary A, Godoy-Ortiz A, Nishio S, Angelergues A, Rubio MJ, Fariñas-Madrid L, Yamaguchi S, Lorusso D, Ray-Coquard I, Manso L, Joly F, Alarcón J, Follana P, Romero I, Lebreton C et al. (2023)
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
Lancet, 403 (10421), 31-43
DOI 10.1016/S0140-6736(23)02405-4, PubMed 38048793

Opheim LØ, Engeskaug I, Bjerre Trent PK, Thorsen L, Staff AC, Nordskar NJ, Utne I, Hagen M, Eriksson AGZ (2023)
Associations between modifiable lifestyle factors and health-related quality of life among endometrial carcinoma survivors - A cross-sectional study
Gynecol Oncol, 179, 52-62
DOI 10.1016/j.ygyno.2023.10.012, PubMed 37924595

Skaali T, Blomhoff R, Lindemann K, Smeland S, Bruheim K, Seland M, Thorsen L (2023)
Self-reported distress and problems after treatment for gynecological cancer - Correlation between a short screening tool and longer measures of anxiety/depression and health-related quality of life
Acta Obstet Gynecol Scand, 103 (2), 387-395
DOI 10.1111/aogs.14709, PubMed 37991142

Valstad H, Eyjolfsdottir B, Wang Y, Kristensen GB, Skeie-Jensen T, Lindemann K (2023)
Pelvic exenteration for vulvar cancer: Postoperative morbidity and oncologic outcome - A single center retrospective analysis
Eur J Surg Oncol, 49 (9), 106958
DOI 10.1016/j.ejso.2023.06.010, PubMed 37349160

Vilming B, Fallås Dahl J, Bentzen AG, Ingebrigtsen VA, Berge Nilsen E, Vistad I, Dørum A, Solheim O, Bjørge L, Zucknick M, Aune G, Lindemann K (2023)
Real-world data on niraparib maintenance treatment in patients with non-gBRCA mutated platinum-sensitive recurrent ovarian cancer
Int J Gynecol Cancer, 33 (12), 1898-1905
DOI 10.1136/ijgc-2023-004484, PubMed 38000795